Publications

Cannabis Regulatory Science:

Spindle T, Sholler D, Cone E, Murphy T, ElSohly M, Winecker R, Flegel R, Bonn-Miller M, Vandrey, R. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. J Am Med Assoc. 2022; 5(7):e2223019

Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid Dose and Label Accuracy In “Edible” Medical Cannabis Products. J Am Med Assoc. 2015; 313; 2491-2493

Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Label accuracy of cannabidiol extracts sold online. J Am Med Assoc. 2017; 318; 1708-1709.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegal R, Hayes E, Vandrey R. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Cross-Over Trial. JAMA Netw Open. 2018; 1; e184841, 1-14.

Arkell TR, Lintzeris N, Ramaekers JG, Vandrey R, Irwin C, Haber PS, Kevin R, McGregor IS. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019; 236; 2713-2724.

Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, Flegel R, Vandrey R. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis. J Anal Tox. 2020; 44; 109-125.

Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, Bigelow GE, Flegel R, Vandrey R. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alc Depend. 2020; 211; 107937.

Schlienz NJ, Spindle TR, Cone EJ, Herrmann ES, Bigelow GE, Mitchell JM, Flegel R, LoDico C, Vandrey R. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alc Depend. ePub March 21, 2020.

Spindle TR, Cone EJ, Herrmann ES, Mitchell JM, Flegel R, LoDico C, Bigelow GE, Vandrey R. Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females. J Anal Toxicol. 2020; 44; 661–671.

Sholler DJ, Strickland JC, Spindle TR, Weerts EM, Vandrey R. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biol ePub Sept 28, 2020.

Arkell T, Spindle T, Kevin R, Vandrey R, McGregor I.  The failings of per se limits to detect cannabis-induced driving impairment: results from a simulated driving study. Traffic Injury Prevention. 2021; 22; 102-107.

Sholler DJ, Moran MB, Dolan SB, Borodovsky JT, Alonso F, Vandrey R, Spindle TR. Use Patterns, Beliefs, Experiences, and Behavioral Economic Demand of Indica and Sativa Cannabis: A Cross-Sectional Survey of Cannabis UsersExp Clin Psychopharm. ePub April 15, 2021.

Spindle TR, Martin E, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of Cognitive and Psychomotor Impairment, Subjective Effects, and Blood THC Concentrations Following Acute Administration of Oral and Vaporized Cannabis. J Psychopharmacol. 2021; 35(7):786-803.

Sholler DJ, Spindle TR, Cone EJ, Goffi E, Kuntz D, Mitchell JM, Winecker RE, Bigelow GE, Flegel R, Vandrey R. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC), and their Metabolites Following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. J Anal Tox. In press.

Spindle TR, Bonn-Miller MO, Vandrey R. Changing Landscape of Cannabis: Novel Products, Formulations, and Methods of Administration. Curr Opin Psychol. 2019; 30; 98-102.

Moore, C. F., & Weerts, E. M. (2021). Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluationsbioRxiv.

Health Effects of Cannabis/Cannabinoids:

Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addic Beh. 2015; 50; 178-181.

Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Beh. 2017; 72; 14-20.

Haug NA, Kieschnick D, Sottile J, Babson KA, Vandrey R, Bonn-Miller MO. Training and practices of cannabis dispensary staff. Cannabis and Cannabinoid Research. 2017; 1; 244-251.

Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, Vandrey R. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Frontiers in Psychiatry. 2021; 12:729800.

Anderson Goodell EM, Nordeck C, Finan PH, Vandrey R, Dunn KE, Thrul J. Feasibility and acceptability of using smartphone-based EMA to assess patterns of prescription opioid and medical cannabis use among individuals with chronic pain. Internet Interv. 2021; 26:100460

Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD.  Therapeutic Potential and Safety Considerations for the Clinical Use of Synthetic Cannabinoids. Pharmacol Biochem Beh. ePub Oct 18, 2020.

Suraev AS, Grunstein RR, D’Rozario AL, Gordon CJ, Bartlett DJ, McGregor IS, Wong K, Yee BJ, Irwin C, Vandrey R, Marshall NS, Arnold J, Hoyos CM. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded proof of concept trial. BMJ Open. In press.

Schlienz NJ, Scalsky R, Martin E, Jackson H, Munson J, Strickland JC, Bonn-Miller MO, Loflin M, Vandrey R. A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health. Cannabis Cannabinoid Res. ePub June 9, 2020.

Bonn-Miller MO, Brunstetter M, Simonian A, Loflin MJE, Vandrey R, Babson KA, Wortzel H.  The long-term, prospective, therapeutic impact of cannabis on PTSD. Cannabis Cannabinoid Res. ePub Dec 9, 2020.

Dunn KE, Bergeria CL, Huhn AS, Speed T, Mun CJ, Vandrey R, Campbell C. Within-Subject, Double-blinded, Randomized, and Placebo-controlled Evaluation of the Combined Effects of the Cannabinoid Dronabinol and the Opioid Hydromorphone in a Human Laboratory Pain Model. Neuropsychopharmacol. ePub April 20, 2021.

Strickland JC, Jackson H, Schlienz NJ, Salpekar JA, Martin EL, Munson J, Bonn-Miller MO, Vandrey R. Cross-sectional and Longitudinal Evaluation of Cannabidiol (CBD) Product Use and Health Among People with EpilepsyEpilepsy Behav.

Moore, C. F., Davis, C. M., Harvey, E. L., Taffe, M. A., & Weerts, E. M. (2021). Appetitive, antinociceptive, and hypothermic effects of vaped and injected Δ-9-tetrahydrocannabinol (THC) in rats: exposure and dose-effect comparisons by strain and sex. Pharmacology Biochemistry and Behavior202, 173116.

Cannabis Use Disorder:

Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alc Depend. 2017; 177; 249-257. 

Herrmann ES, Weerts E, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Expand Clin Psychopharm. 2015; 23; 415-421.

Schlienz NJ, Lee DL, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alc Depend. 2018; 187; 254-260.

Thrul J, Gubner NR, Nguyen N, Nguyen C, Goodell EA, Holmes LM, Vandrey RG, Ling PM. Perceived reward from using cigarettes with alcohol or cannabis and concurrent use: A smartphone-based daily diary study. Addictive Behaviors. 2021; 114; 106747.

Spindle TR, Kuwabara H, Eversole A, Nandi A, Vandrey R, Antoine DG, Umbricht A, Guarda AS, Wong DF, Weerts EM. Brain Imaging of Cannabinoid Type I (CB1) Receptors in Women with Cannabis Use Disorder and Male and Female Healthy Controls. Addict Biol. In press.